Regulatory milestones

Aegerion Pharmaceuticals Inc. (NASDAQ:AEGR) gained $3.69 (23%) to $19.65 last week after FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 13-2 that efficacy and safety data for lomitapide support approval to treat homozygous familial hypercholesterolemia (hoFH).